Ordering and Reimbursement

Order VABOMERE™ (meropenem and vaborbactam) Using Standard Ordering Procedure Through Your Wholesaler

  • VABOMERE is a wholesaler-stocked product
  • If VABOMERE is not available at your wholesaler, the wholesaler can coordinate a drop shipment via Next Day Saver from a Melinta primary distribution provider
  • Download the Order Sheet for more information

2 single-dose vials = 4 g dose

VABOMERE™ 4 g (2 g meropenem and 2 g vaborbactam)



Download order Sheet

Coding and Reimbursement

Covers the coding requirements, coding systems, and their application when VABOMERE is administered

  • Lists ICD-10 codes and transition of care codes to facilitate timely claims processing and reduce the risk of denied claims
  • Addresses coverage and payment information pertaining to Medicare, Medicaid, and commercial payers, in inpatient and outpatient settings including long-term acute care and home infusion reimbursement
  • Includes sample CMS 1450 and CMS 1500 billing forms
  • See Coding and Billing Reference Guide for details

New Technology Add-on Payments (NTAP) for VABOMERE Effective October 1, 2018

Under the Medicare program, the Centers for Medicare and Medicaid Services (CMS) provides a process for identifying and ensuring adequate payment for new medical services and technologies. In particular, technologies that qualify as “new” and meet certain other specified criteria may be considered for “new technology add-on payments" (NTAP).

NTAP is an add-on payment that applies to Medicare inpatients only; specifically, it is an additional payment to the Diagnostic Related Group (DRG)-based reimbursement that otherwise applies to the reimbursement paid for a Medicare beneficiary’s inpatient stay.

Effective October 1, 2018, the start of the 2019 fiscal year, Medicare inpatient stays that involve the administration of VABOMERE may be eligible for NTAP. As determined by CMS, $5,544 is the maximum NTAP amount for a Medicare inpatient case involving the administration of VABOMERE in FY 2019.

Please check back prior to October 1st for additional information, including coding and an updated Reimbursement Guide.


The content of this guide is general in nature, strictly for informational purposes only, and does not cover all situations or all payers’ policies and guidance. The information provided in this guide was obtained from third-party sources and is subject to change without notice as a result of changes in reimbursement laws, regulations, rules, policies, and payment amounts. This guide is not intended to provide clinical practice guidelines.

Melinta Therapeutics, Inc. (Melinta) cannot guarantee, and is not responsible for, the payment of any claim. The coding, coverage, and payment of VABOMERE may vary by payer, plan, patient, and setting of care. Coding determinations and analysis should always be independently researched and assessed. For more information, please check with individual payers for specific coding, coverage, and payment requirements. It is the sole responsibility of the healthcare provider to code properly and to ensure the accuracy of all claims submitted for reimbursement. Additionally, as a prerequisite for submitting a claim, the provider is responsible for ensuring that all services are medically necessary and properly supported in the patient’s medical records. Melinta specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this guide.



Get details about VABOMERE dosing



Register for updates and resources

Reference: 1. Vabomere [package insert]. Lincolnshire, IL: Melinta Therapeutics, Inc.; 2018.


VABOMERE™ (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.



VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.

Warnings and Precautions

  • Hypersensitivity reactions were reported in patients treated with VABOMERE in the clinical trials. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions and serious skin reactions have been reported in patients receiving therapy with beta-lactam antibacterial drugs. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam antibacterial drug. If an allergic reaction to VABOMERE occurs, discontinue the drug immediately.
  • Seizures and other adverse Central Nervous System (CNS) experiences have been reported during treatment with meropenem, which is a component of VABOMERE. Close adherence to the recommended dosage regimens is urged, especially in patients with known factors that predispose to convulsive activity.
  • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including VABOMERE, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
  • The concomitant use of VABOMERE and valproic acid or divalproex sodium is generally not recommended. Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. If administration of VABOMERE is necessary, consider supplemental anticonvulsant therapy.
  • In patients with renal impairment, thrombocytopenia has been observed in patients treated with meropenem, but no clinical bleeding has been reported.
  • Alert patients receiving VABOMERE on an outpatient basis regarding adverse reactions such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment.
  • Prescribing VABOMERE in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of drug-resistant bacteria.
  • As with other antibacterial drugs, prolonged use of VABOMERE may result in overgrowth of nonsusceptible organisms.

Adverse Reactions

The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.

Please see Full Prescribing Information.